| Literature DB >> 34853705 |
Dariusz Dobrowolski1,2, Boguslawa Orzechowska-Wylegala3, Bogumil Wowra1, Ewa Wróblewska-Czajka1, Maria Grolik1, Edward Wylegala1.
Abstract
PURPOSE: To analyse the recurrence of superficial neovascularisation after previous corneal surface reconstruction with cultivated corneal epithelial cells.Entities:
Year: 2021 PMID: 34853705 PMCID: PMC8629671 DOI: 10.1155/2021/8499640
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Types of ocular burns and involvement of corneal surface in Dua's scale and in clock hours of the limbus involvement in each patient.
| Patient | Burn | Burning agent | Dua scale rate | Initial involvement of the limbus in clock hours |
|---|---|---|---|---|
| 1 | Thermal | Steam | IV | 7 |
| 2 | Chemical | Alkaline | V | 11 |
| 3 | Chemical | Alkaline | IV | 8 |
| 4 | Chemical | Alkaline | V | 11 |
| 5 | Chemical | Alkaline | V | 10 |
| 6 | Chemical | Alkaline | V | 11 |
| 7 | Chemical | Acidic | IV | 8 |
| 8 | Chemical | Alkaline | VI | 12 |
| 9 | Chemical | Alkaline | V | 11 |
| 10 | Chemical | Alkaline | VI | 12 |
| 11 | Chemical | Alkaline | VI | 12 |
| 12 | Chemical | Alkaline | V | 3 |
| 13 | Chemical | Alkaline | V | 9 |
| 14 | Chemical | Alkaline | V | 11 |
| 15 | Chemical | Alkaline | VI | 12 |
| 16 | Chemical | Alkaline | V | 10 |
| 17 | Chemical | Alkaline | VI | 12 |
| 18 | Chemical | Alkaline | VI | 12 |
| 19 | Chemical | Alkaline | V | 11 |
| 20 | Chemical | Alkaline | V | 11 |
| 21 | Chemical | Alkaline | V | 11 |
| 22 | Chemical | Alkaline | IV | 8 |
| 23 | Chemical | Alkaline | IV | 8 |
| 24 | Chemical | Alkaline | V | 10 |
| 25 | Chemical | Alkaline | V | 11 |
| 26 | Chemical | Alkaline | V | 11 |
| 27 | Chemical | Alkaline | V | 11 |
| 28 | Chemical | Acidic | IV | 8 |
| 29 | Chemical | Alkaline | IV | 7 |
| 30 | Chemical | Alkaline | V | 10 |
| 31 | Chemical | Alkaline | VI | 12 |
| 32 | Chemical | Alkaline | VI | 12 |
| 33 | Chemical | Alkaline | VI | 12 |
| 34 | Chemical | Alkaline | V | 9 |
| 35 | Chemical | Alkaline | V | 10 |
| 36 | Chemical | Alkaline | V | 11 |
| 37 | Chemical | Alkaline | VI | 12 |
| 38 | Chemical | Alkaline | V | 10 |
| 39 | Thermal | Steam | V | 9 |
| 40 | Chemical | Alkaline | V | 11 |
| 41 | Chemical | Alkaline | V | 9 |
| 42 | Chemical | Alkaline | VI | 12 |
| 43 | Chemical | Alkaline | IV | 7 |
| 44 | Chemical | Alkaline | IV | 6 |
| 45 | Chemical | Alkaline | VI | 12 |
| 46 | Chemical | Alkaline | VI | 12 |
| 47 | Chemical | Alkaline | V | 11 |
| 48 | Chemical | Alkaline | V | 11 |
Figure 1Kaplan–Mayer curve showing graft survival rate.
Patients' overview range of conjunctival ingrowth (clock hours) in each 6-month period of follow-up.
| Pat. | Dua scale rating | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 | 54 | 60 | 66 | 72 | 78 | 84 | 90 | 96 | 102 | 108 | 114 | 120 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Months after surgery, R-rejected from the study (retransplantation or consent withdrawal) number of clock hours of conjunctival neovascularisation on the corneal surface (0-initial number of clock hours of the cornea covered by conjunctiva) | |||||||||||||||||||||||
| 1 | IV | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 2 | V | 11 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| 3 | IV | 8 | 0 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| 4 | V | 11 | 2 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | R | ||||||||
| 5 | V | 10 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| 6 | V | 11 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |
| 7 | IV | 8 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| 8 | VI | 12 | 10 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | R | ||||||||||
| 9 | V | 11 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |
| 10 | VI | 12 | 8 | 9 | 10 | 10 | 10 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | R | ||||||||
| 11 | VI | 12 | 12 | 12 | 12 | 12 | R | ||||||||||||||||
| 12 | V | 3 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | R | ||||||||
| 13 | V | 9 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | |
| 14 | V | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 15 | VI | 12 | 4 | 4 | 4 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| 16 | V | 10 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| 17 | VI | 12 | 6 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | R | |||||||||||
| 18 | VI | 12 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | R | ||||||||||
| 19 | V | 11 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| 20 | V | 11 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |
| 21 | V | 11 | 12 | 12 | 12 | 12 | R | ||||||||||||||||
| 22 | IV | 8 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| 23 | IV | 8 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |
| 24 | V | 10 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| 25 | V | 11 | 7 | 9 | 9 | 9 | 9 | 9 | 9 | R | |||||||||||||
| 26 | V | 11 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| 27 | V | 11 | 3 | 6 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | R | ||||||||
| 28 | IV | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 29 | IV | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 30 | V | 10 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| 31 | VI | 12 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | R | ||||||
| 32 | VI | 12 | 2 | 8 | 12 | R | |||||||||||||||||
| 33 | VI | 12 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||
| 34 | V | 9 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 7 | 8 | R | ||||||||||
| 35 | V | 10 | 0 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| 36 | V | 11 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| 37 | VI | 12 | 8 | 10 | 10 | 10 | 10 | 10 | 11 | R | |||||||||||||
| 38 | V | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 39 | V | 9 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||
| 40 | V | 11 | 6 | 8 | 9 | 9 | 9 | 10 | 10 | R | |||||||||||||
| 41 | V | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 42 | VI | 12 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||
| 43 | IV | 7 | 4 | 4 | 4 | 4 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||
| 44 | IV | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 45 | VI | 12 | 6 | 6 | 6 | 7 | 7 | 8 | R | ||||||||||||||
| 46 | VI | 12 | 7 | 12 | 12 | 12 | 12 | R | |||||||||||||||
| 47 | V | 11 | 3 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | R | |||||
| 48 | V | 11 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||
Figure 2Diagram of patients' follow-up.
Figure 3Average of clock hours of conjunctival invasion in success group over 120 months.
Figure 4Average of clock hours of conjunctival invasion in failure group over 120 months.
Figure 5Mean visual acuity obtained by patients depending on the degree of conjunctival recurrence in the consecutive corneal quadrants.
Figure 6Analysis of corneal vascularisation in moderate (a) and advanced (b) conjunctival ingrowth assessed with confocal microscopy support.